1130 related articles for article (PubMed ID: 12660585)
21. [Hypotensive action of 0.5% carteolol versus 0.1% timolol in patients with intraocular hypertension].
Allaire C; Trinquand C; Nordmann JP; Dascotte JC; George JL; Lesure P; Rouland JF; Khaitrine L; Sirbat D
J Fr Ophtalmol; 1995; 18(1):22-6. PubMed ID: 7738291
[TBL] [Abstract][Full Text] [Related]
22. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
24. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
[TBL] [Abstract][Full Text] [Related]
25. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
26. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.
Choplin N; Bernstein P; Batoosingh AL; Whitcup SM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S19-25. PubMed ID: 15016558
[TBL] [Abstract][Full Text] [Related]
27. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension.
Mundorf TK; Ogawa T; Naka H; Novack GD; Crockett RS;
Clin Ther; 2004 Apr; 26(4):541-51. PubMed ID: 15189751
[TBL] [Abstract][Full Text] [Related]
28. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
29. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma.
Chew PT; Aung T; Aquino MV; Rojanapongpun P;
Ophthalmology; 2004 Mar; 111(3):427-34. PubMed ID: 15019314
[TBL] [Abstract][Full Text] [Related]
30. Intraocular pressure elevation within the first 24 hours after cataract surgery in patients with glaucoma or exfoliation syndrome.
Levkovitch-Verbin H; Habot-Wilner Z; Burla N; Melamed S; Goldenfeld M; Bar-Sela SM; Sachs D
Ophthalmology; 2008 Jan; 115(1):104-8. PubMed ID: 17561259
[TBL] [Abstract][Full Text] [Related]
31. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
32. Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost.
Lupinacci AP; Netland PA; Fung KH; Evans D; Zhao Y
Adv Ther; 2008 Mar; 25(3):231-9. PubMed ID: 18369537
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
34. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC
Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
[TBL] [Abstract][Full Text] [Related]
35. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
Williams RD; Novack GD; van Haarlem T; Kopczynski C;
Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
[TBL] [Abstract][Full Text] [Related]
36. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.
Toris CB; Zhan G; Fan S; Dickerson JE; Landry TA; Bergamini MV; Camras CB
J Glaucoma; 2007 Mar; 16(2):189-95. PubMed ID: 17473728
[TBL] [Abstract][Full Text] [Related]
37. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
[TBL] [Abstract][Full Text] [Related]
38. Effects of latanoprost 50 micrograms/ml on Chinese patients with primary open-angle glaucoma and ocular hypertension.
Liu CJ; Chou JC; Hsu WM; Liu JH
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):703-9. PubMed ID: 10533300
[TBL] [Abstract][Full Text] [Related]
39. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure.
Koseki N; Araie M; Tomidokoro A; Nagahara M; Hasegawa T; Tamaki Y; Yamamoto S
Ophthalmology; 2008 Nov; 115(11):2049-57. PubMed ID: 18672290
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension.
Suzuki ER; Franklin LM; da Silva LJ; Figueiredo CR; Netto JA; Batista WD
Curr Med Res Opin; 2006 Sep; 22(9):1799-805. PubMed ID: 16968583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
